|Bid||2.7000 x 1400|
|Ask||2.7100 x 1300|
|Day's Range||2.6200 - 2.7150|
|52 Week Range||2.3500 - 5.4000|
|Beta (3Y Monthly)||1.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
SUNNYVALE, Calif. , Oct. 10, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2019 on Tuesday, October 29, 2019 after the market close. ...
SUNNYVALE, Calif., Sept. 19, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) today published an informational guide designed to help radiation oncology practices understand the complexities of the much-anticipated proposed Medicare & Medicaid reimbursement changes. Titled, "Thriving Under the Radiation Oncology Alternative Payment Model: A Definitive Guide to a New Reality," the guide aims to help radiation oncology professionals understand the changes outlined in the Radiation Oncology – Alternative Payment Model (RO-APM). "We believe that the proposed alternative payment model will reshape economic realities and evolve clinical best practices for radiation oncologists," said Joshua H. Levine, President and Chief Executive Officer of Accuray.
SUNNYVALE, Calif., Sept. 17, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announces that The Lancet Oncology, a high impact and leading global peer-reviewed oncology journal, has published patient- and clinician-reported outcomes data from the PACE — Prostate Advances in Comparative Evidence — trial in its most recent issue. While further investigation is planned, data reported in the journal indicate that the level of grade 2 or higher acute genitourinary toxicity in the stereotactic body radiation therapy (SBRT) arm of the trial is lower for patients treated with the Accuray CyberKnife® System than it is for patients treated on a conventional linear accelerator. SBRT involves the delivery of very high doses of externally-administered radiation over a small number of treatment sessions, offering convenience for patients, compared to conventional radiation therapy which requires a substantially longer course of treatment.
SUNNYVALE, Calif., Sept. 16, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced that, on September 11, 2019, China's Customs Tariff Commission of the State Council issued a tariff exemption for medical linear accelerators. The tariff exemption, which will be effective September 17, 2019 and is scheduled to last for one year, applies to the additional tariffs China imposed on U.S. products effective as of August 23, 2018. Accuray expects to benefit from such tariff exemption. "We applaud the recent decision to exempt medical linear accelerators," said Josh Levine, president and chief executive officer, Accuray.
SUNNYVALE, Calif., Sept. 12, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) strengthened its Board of Directors with the appointment of James (Jim) M. Hindman, effective as of September 6, 2019, and expanding the company's Board to nine members. Mr. Hindman, an experienced healthcare executive with a 30-year tenure at Allergan, Inc., is an accomplished financial executive with expertise in maximizing shareholder value. Mr. Hindman will serve on the Board's Audit Committee.
SUNNYVALE, Calif., Sept. 10, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the Geisinger Medical Center radiation oncology team is first in Pennsylvania to treat cancer patients with the innovative Radixact® System. The hospital, located in Danville, is part of Geisinger Health System, one of the United States' most innovative health services organizations. The system's speed, versatility and flexibility will enable the clinical team to provide a treatment option for virtually any case for which radiation therapy is prescribed, including large tumors or multiple tumors throughout the body, hard-to-reach tumors, and tumors that have recurred, including those in patients who may not be candidates for retreatment with traditional delivery systems.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Presentations will be Live Webcast and Commence at 3:00pm CT SUNNYVALE, Calif. , Sept. 4, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will host an Investor ...
Accuray Inc (ARAY) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019. Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Continue reading...
SUNNYVALE, Calif., Aug. 21, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that physicians at the Froedtert & the Medical College of Wisconsin ("MCW") Clinical Cancer Center at Froedtert Hospital in Milwaukee, Wisconsin have treated the first cancer patient in the world, a 45-year-old man with lung cancer, using the Radixact® System with Synchrony® motion tracking and correction technology1. With the addition of Synchrony, the Radixact System was able to track the lung tumor in real-time as it moved with the patient's breathing and automatically adjust the radiation beam to keep it targeted on the tumor.
Accuray (ARAY) delivered earnings and revenue surprises of -166.67% and 1.14%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
SUNNYVALE, Calif. , Aug. 15, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2019 . Q4 Fiscal 2019 and Recent ...
Accuray (NASDAQ: ARAY ) unveils its next round of earnings this Thursday, August 15. Here is Benzinga's everything-that-matters guide for the earnings announcement. Earnings and Revenue Based on Accuray ...